| Ceftolozane | CUBIST Pharma | ||
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ; Powder |
Less Than $1000 mn
|
||
| None | None | ||
|
Less Than 5
|
None | ||
| None | None | ||
| ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms: • Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years old). • Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis, in adult and pediatric patients (birth to less than 18 years old). • Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP), in adult patients 18 years and older. | |||
|
Yes
| |||
| Zerbaxa | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||
| ****** ********* | ******* *** ******** ************** ********** | ******* *** ******** ************** ********** | ********** ******** ************ | ********** ******** ************ | *********** ********** ************ | *********** ********** ************ | ***********-********** ************** ************ | ***********-********** ************** ************ | *********** ********** ************ | ***** ***** ** *********** | ******** ********** **** ***********/********** ** ******** ****** ******** ***** ******** | ******** ********** **** ***********/********** ** ******** ****** ******** ***** ******** | ********* ** ************* ********* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|